These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8880685)

  • 1. Effects of seven days of galactose feeding and aldose reductase inhibition on mast cells and vessel morphometry in rat sciatic nerve.
    Brett FM; Kalichman MW; Calcutt NA; Mizisin AP
    J Neurol Sci; 1996 Sep; 141(1-2):6-12. PubMed ID: 8880685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of macrophage chemotaxis and peripheral nerve regeneration in normal and hyperglycemic rats by the aldose reductase inhibitor Tolrestat.
    Calcutt NA; McMurray HF; Moorhouse DF; Bache M; Parthasarathy S; Powell HC; Mizisin AP
    Exp Neurol; 1994 Aug; 128(2):226-32. PubMed ID: 8076666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
    Forster HG; ter Wee PM; Hohman TC; Epstein M
    Diabetologia; 1996 Aug; 39(8):907-14. PubMed ID: 8858212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cell degranulation and blood-nerve barrier permeability in rat sciatic nerve after 7 days of hyperglycemia.
    Kalichman MW; Powell HC; Calcutt NA; Mizisin AP
    Am J Physiol; 1995 Feb; 268(2 Pt 2):H740-8. PubMed ID: 7864200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine triphosphatase in nerves and ganglia of rats with streptozotocin-induced diabetes or galactosaemia; effects of aldose reductase inhibition.
    Lambourne JE; Brown AM; Calcutt N; Tomlinson DR; Willars GB
    Diabetologia; 1988 Jun; 31(6):379-84. PubMed ID: 2970984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iris vasculopathy in galactose-fed rats.
    Caspers-Velu LE; Wadhwani KC; Rapoport SI; Kador PF
    Exp Eye Res; 1999 Feb; 68(2):211-21. PubMed ID: 10068486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy.
    Sredy J; Sawicki DR; Notvest RR
    J Diabet Complications; 1991; 5(1):42-7. PubMed ID: 1830318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes impairs sciatic nerve hyperemia induced by surgical trauma: implications for diabetic neuropathy.
    Ido Y; Chang K; LeJeune W; Tilton RG; Monafo WW; Williamson JR
    Am J Physiol; 1997 Jul; 273(1 Pt 1):E174-84. PubMed ID: 9252494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats.
    Mizisin AP; Calcutt NA; DiStefano PS; Acheson A; Longo FM
    Diabetes; 1997 Apr; 46(4):647-52. PubMed ID: 9075806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
    Wrobel J; Millen J; Sredy J; Dietrich A; Gorham BJ; Malamas M; Kelly JM; Bauman JG; Harrison MC; Jones LR
    J Med Chem; 1991 Aug; 34(8):2504-20. PubMed ID: 1908522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat.
    Robison WG; Kador PF; Akagi Y; Kinoshita JH; Gonzalez R; Dvornik D
    Diabetes; 1986 Mar; 35(3):295-9. PubMed ID: 3081393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoguanidine does not inhibit aldose reductase activity in galactose-fed rats.
    Dvornik D; Hohman TC; Basso MD
    J Diabetes Complications; 1996; 10(1):23-30. PubMed ID: 8639971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase, diabetes, and thickening of the retinal inner limiting membrane.
    Nagata M; Robison WG
    Invest Ophthalmol Vis Sci; 1987 Nov; 28(11):1867-9. PubMed ID: 3117719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schwann cell injury is attenuated by aldose reductase inhibition in galactose intoxication.
    Mizisin AP; Powell HC
    J Neuropathol Exp Neurol; 1993 Jan; 52(1):78-86. PubMed ID: 8426189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
    Frank RN; Amin R; Kennedy A; Hohman TC
    Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolrestat pharmacokinetics in rat peripheral nerve.
    Dvornik D; Millen J; Hicks DR; Kraml M
    J Diabetes Complications; 1994; 8(1):18-26. PubMed ID: 8167382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve.
    Calcutt NA; Mizisin AP; Kalichman MW
    Eur J Pharmacol; 1994 Jan; 251(1):27-33. PubMed ID: 8137868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors.
    Jacot JL; Hosotani H; Glover JP; Lois N; Robison WG
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):169-80. PubMed ID: 9572543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
    Bank N; Coco M; Aynedjian HS
    Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.